Management of HR-positive, HER2-negative advanced breast cancer with CDK4/6 inhibitors: Effect of online education on clinician knowledge, competence and confidence

被引：0
|
作者：
Fisher, G. [1 ]
Middleton, D. [2 ]
Day, C. [3 ]
Di Leo, A. [4 ]
机构：
[1] GeoFish Med Mkt Ltd, Med Strategy, Prestatyn, Wales
[2] Medscape, Global Educ, New York, NY USA
[3] Medscape, Global Educ, London, England
[4] Hosp Prato, Ist Toscano Tumori, Sandro Pitigliani Med Oncol Unit, Prato, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
361 (PB-15
引用
收藏
页码：S102 / S102
页数：1
相关论文
共 50 条
  • [21] Impact of PET and PET/CT Radiotracer for Evaluating Efficacy of CDK4/6 Inhibitor Therapy in HR-Positive HER2-Negative Metastatic Breast Cancer
    Imamovic, Elma
    Veledar, Anisa
    Kalic, Zerina
    Softic, Adna
    Mrdanovic, Emina
    Smajlhodzic-Deljo, Merima
    MEDICON 2023 AND CMBEBIH 2023, VOL 1, 2024, 93 : 345 - 350
  • [22] Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis
    Kubeczko, Marcin
    Jarzab, Michal
    Gabrys, Dorota
    Krzywon, Aleksandra
    Cortez, Alexander J.
    Xu, Amy J.
    RADIOTHERAPY AND ONCOLOGY, 2023, 187
  • [23] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Matutino, Adriana
    Amaro, Carla
    Verma, Sunil
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [24] Predictive biomarkers for CDK4/6 inhibitors: Effect of online education on clinician knowledge
    Fisher, G.
    Middleton, D.
    Day, C.
    Andre, F.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S102 - S102
  • [25] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
  • [26] Exemestane plus entinostat in HR-positive/HER2-negative breast cancer?
    Lichert, Frank
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (01) : 18 - 18
  • [27] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257
  • [28] Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer Reply
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Toi, Masakazu
    Martin, Miguel
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (13) : 1507 - +
  • [29] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
    Nardin, Simone
    Del Mastro, Lucia
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [30] Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study
    Wu, Yun
    Mo, Hongnan
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    Ma, Fei
    Xu, Binghe
    THORACIC CANCER, 2024, 15 (12) : 965 - 973
12345